title: Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered.
abstract: We compared the antibody response to Haemophilus influenzae type b capsular polysaccharide (PRP) after 1, 2, or 3 doses of a diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccine combined with a PRP-tetanus conjugate (PRP-T) vaccine, followed by separate injections of DTaP and PRP-T vaccines for the last 1 or 2 doses. Healthy infants were recruited from pediatric practices and were immunized according to recommended schedules. A significant decrease in the mean anti-PRP (from 5.25 to 2.68 microg/mL) and anti-tetanus toxoid antibody responses (from 0.13 to 0.09 Eq/mL) was observed as the number of doses of the DTaP/PRP-T combination vaccine increased (P<.02 and P=.01, respectively). In contrast, the mean anti-diphtheria toxoid antibody response increased with increasing numbers of DTaP/PRP-T doses (P=.0001). The effects of interference were not eliminated by the completion of the primary series with 1 or 2 doses of the DTaP and PRP-T vaccines given separately.
authors.affiliation: Department of Pediatrics, Section of Infectious Diseases and General Pediatrics, University of Chicago, Chicago, IL 60637, USA. rsd2@midway.uchicago.edu
authors.forename: R S
authors.initials: RS
authors.lastname: Daum
authors.forename: C E
authors.initials: CE
authors.lastname: Zenko
authors.forename: G Z
authors.initials: GZ
authors.lastname: Given
authors.forename: G A
authors.initials: GA
authors.lastname: Ballanco
authors.forename: H
authors.initials: H
authors.lastname: Parikh
authors.forename: K
authors.initials: K
authors.lastname: Germino
mesh_terms: D000907:Antibodies, Bacterial / Q000032:analysis*; D000914:Antibodies, Viral / Q000032:analysis*; D004165:Diphtheria / Q000517:prevention & control; D004168:Diphtheria Toxoid / Q000276:immunology; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage* / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006192:Haemophilus Infections / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007223:Infant; D008297:Male; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000276:immunology; D013742:Tetanus / Q000517:prevention & control; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000276:immunology; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000008:administration & dosage; D014917:Whooping Cough / Q000517:prevention & control
chemical_list: D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D004168:Diphtheria Toxoid; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate